Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2025-05-08 | Kvartalsrapport 2025-Q1 |
2025-02-13 | Bokslutskommuniké 2024 |
2024-10-23 | Extra Bolagsstämma 2025 |
2024-10-21 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-05-23 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2024-05-22 | Årsstämma |
2024-05-08 | Kvartalsrapport 2024-Q1 |
2024-02-08 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-24 | Kvartalsrapport 2023-Q2 |
2023-05-25 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2023-05-24 | Årsstämma |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-11-03 | Kvartalsrapport 2022-Q3 |
2022-08-04 | Kvartalsrapport 2022-Q2 |
2022-05-20 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2022-05-19 | Årsstämma |
2022-04-21 | Kvartalsrapport 2022-Q1 |
2022-02-09 | Bokslutskommuniké 2021 |
2021-11-04 | Kvartalsrapport 2021-Q3 |
2021-08-05 | Kvartalsrapport 2021-Q2 |
2021-05-20 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2021-05-19 | Årsstämma |
2021-04-22 | Kvartalsrapport 2021-Q1 |
2021-02-11 | Bokslutskommuniké 2020 |
2020-11-30 | Extra Bolagsstämma 2020 |
2020-11-05 | Kvartalsrapport 2020-Q3 |
2020-08-06 | Kvartalsrapport 2020-Q2 |
2020-05-20 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2020-05-19 | Årsstämma |
2020-04-23 | Kvartalsrapport 2020-Q1 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-11-14 | Kvartalsrapport 2019-Q3 |
2019-08-08 | Kvartalsrapport 2019-Q2 |
2019-05-24 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2019-05-23 | Årsstämma |
2019-04-25 | Kvartalsrapport 2019-Q1 |
2019-04-04 | Extra Bolagsstämma 2019 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-11-15 | Kvartalsrapport 2018-Q3 |
2018-08-09 | Kvartalsrapport 2018-Q2 |
2018-05-18 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2018-05-17 | Årsstämma |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-03-19 | Extra Bolagsstämma 2018 |
2018-02-15 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-08-10 | Kvartalsrapport 2017-Q2 |
2017-06-15 | Årsstämma |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Bokslutskommuniké 2016 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-11 | Kvartalsrapport 2016-Q2 |
2016-05-27 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2016-05-26 | Årsstämma |
2016-04-28 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-11-06 | Kvartalsrapport 2015-Q3 |
2015-06-12 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2015-06-11 | Årsstämma |
2015-04-23 | Kvartalsrapport 2015-Q1 |
2015-02-11 | Bokslutskommuniké 2014 |
2014-12-01 | Extra Bolagsstämma 2014 |
2014-11-05 | Kvartalsrapport 2014-Q3 |
2014-08-07 | Kvartalsrapport 2015-Q2 |
2014-05-16 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2014-05-15 | Årsstämma |
2014-04-24 | Kvartalsrapport 2014-Q1 |
2014-02-13 | Bokslutskommuniké 2013 |
2014-01-16 | 15-7 2014 |
2013-11-07 | Kvartalsrapport 2013-Q3 |
2013-08-07 | Kvartalsrapport 2013-Q2 |
2013-05-16 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2013-05-15 | Årsstämma |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-14 | Bokslutskommuniké 2012 |
2013-01-10 | 15-6 2013 |
2012-11-09 | Kvartalsrapport 2012-Q3 |
2012-09-11 | Extra Bolagsstämma 2012 |
2012-08-10 | Kvartalsrapport 2012-Q2 |
2012-06-14 | Kapitalmarknadsdag 2012 |
2012-05-11 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2012-05-10 | Årsstämma |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-02-16 | Bokslutskommuniké 2011 |
2012-01-12 | 15-7 2012 |
2011-11-03 | Kvartalsrapport 2011-Q3 |
2011-08-11 | Kvartalsrapport 2011-Q2 |
2011-05-06 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2011-05-05 | Årsstämma |
2011-04-28 | Kvartalsrapport 2011-Q1 |
2011-02-10 | Bokslutskommuniké 2010 |
2010-10-27 | Kvartalsrapport 2010-Q3 |
2010-08-11 | Kvartalsrapport 2010-Q2 |
2010-05-07 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2010-05-06 | Årsstämma |
2010-04-22 | Kvartalsrapport 2010-Q1 |
2010-02-11 | Bokslutskommuniké 2009 |
2009-11-05 | Kvartalsrapport 2009-Q3 |
2009-08-06 | Kvartalsrapport 2009-Q2 |
2009-05-08 | X-dag ordinarie utdelning ACTI 0.00 SEK |
2009-05-07 | Årsstämma |
2009-04-23 | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
SECOND QUARTER IN BRIEF
- Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)
- Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22)
- Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer were presented at ASCO 2024 (May 28)
EVENTS AFTER THE END OF THE PERIOD
- Active Biotech entered agreement for a clinical study of tasquinimod in myelofibrosis (July 1)
- Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)
FINANCIAL SUMMARY
SEK M | Apr-Jun | Jan-Jun | Full-year | ||
2024 2023 | 2024 2023 | 2023 | |||
Net sales | - | - | - | - | - |
Operating profit/loss | -10.7 | -11.3 | -21.4 | -23.1 | -46.5 |
Profit/loss after tax | -10.6 | -11.2 | -21.1 | -22.7 | -45.8 |
Earnings per share (SEK) | -0.03 | -0.04 | -0.06 | -0.09 | -0.17 |
Cash and cash equivalents (at close of period) | 13.9 | 15.7 | 36.2 |
The report is also available at www.activebiotech.com
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies are being prepared. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-22 08:30 CEST.